![31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports /](/search/themes/bootstrap3/images/libros.png)
31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports /
Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Texto biblioteca |
| Language: | eng |
| Published: |
Berlin, Heidelberg : Springer Berlin Heidelberg,
2002
|
| Subjects: | Medicine., Anesthesiology., Critical care medicine., Blood transfusion., Hematology., Pediatrics., Medicine & Public Health., Blood Transfusion Medicine., Intensive / Critical Care Medicine., |
| Online Access: | http://dx.doi.org/10.1007/978-3-642-59383-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
KOHA-OAI-TEST:219344 |
|---|---|
| record_format |
koha |
| institution |
COLPOS |
| collection |
Koha |
| country |
México |
| countrycode |
MX |
| component |
Bibliográfico |
| access |
En linea En linea |
| databasecode |
cat-colpos |
| tag |
biblioteca |
| region |
America del Norte |
| libraryname |
Departamento de documentación y biblioteca de COLPOS |
| language |
eng |
| topic |
Medicine. Anesthesiology. Critical care medicine. Blood transfusion. Hematology. Pediatrics. Medicine & Public Health. Hematology. Pediatrics. Anesthesiology. Blood Transfusion Medicine. Intensive / Critical Care Medicine. Medicine. Anesthesiology. Critical care medicine. Blood transfusion. Hematology. Pediatrics. Medicine & Public Health. Hematology. Pediatrics. Anesthesiology. Blood Transfusion Medicine. Intensive / Critical Care Medicine. |
| spellingShingle |
Medicine. Anesthesiology. Critical care medicine. Blood transfusion. Hematology. Pediatrics. Medicine & Public Health. Hematology. Pediatrics. Anesthesiology. Blood Transfusion Medicine. Intensive / Critical Care Medicine. Medicine. Anesthesiology. Critical care medicine. Blood transfusion. Hematology. Pediatrics. Medicine & Public Health. Hematology. Pediatrics. Anesthesiology. Blood Transfusion Medicine. Intensive / Critical Care Medicine. Scharrer, Inge. editor. Schramm, Wolfgang. editor. SpringerLink (Online service) 31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports / |
| description |
Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have. |
| format |
Texto |
| topic_facet |
Medicine. Anesthesiology. Critical care medicine. Blood transfusion. Hematology. Pediatrics. Medicine & Public Health. Hematology. Pediatrics. Anesthesiology. Blood Transfusion Medicine. Intensive / Critical Care Medicine. |
| author |
Scharrer, Inge. editor. Schramm, Wolfgang. editor. SpringerLink (Online service) |
| author_facet |
Scharrer, Inge. editor. Schramm, Wolfgang. editor. SpringerLink (Online service) |
| author_sort |
Scharrer, Inge. editor. |
| title |
31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports / |
| title_short |
31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports / |
| title_full |
31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports / |
| title_fullStr |
31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports / |
| title_full_unstemmed |
31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports / |
| title_sort |
31st hemophilia symposium hamburg 2000 [electronic resource] : epidemiology inhibitors in hemophilia therapy and monitoring of bleeds in acute and intensive care medicine pediatric hemostaseology case reports / |
| publisher |
Berlin, Heidelberg : Springer Berlin Heidelberg, |
| publishDate |
2002 |
| url |
http://dx.doi.org/10.1007/978-3-642-59383-3 |
| work_keys_str_mv |
AT scharreringeeditor 31sthemophiliasymposiumhamburg2000electronicresourceepidemiologyinhibitorsinhemophiliatherapyandmonitoringofbleedsinacuteandintensivecaremedicinepediatrichemostaseologycasereports AT schrammwolfgangeditor 31sthemophiliasymposiumhamburg2000electronicresourceepidemiologyinhibitorsinhemophiliatherapyandmonitoringofbleedsinacuteandintensivecaremedicinepediatrichemostaseologycasereports AT springerlinkonlineservice 31sthemophiliasymposiumhamburg2000electronicresourceepidemiologyinhibitorsinhemophiliatherapyandmonitoringofbleedsinacuteandintensivecaremedicinepediatrichemostaseologycasereports |
| _version_ |
1756270013351723008 |
| spelling |
KOHA-OAI-TEST:2193442018-07-30T23:56:31Z31st Hemophilia Symposium Hamburg 2000 [electronic resource] : Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports / Scharrer, Inge. editor. Schramm, Wolfgang. editor. SpringerLink (Online service) textBerlin, Heidelberg : Springer Berlin Heidelberg,2002.engSome 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.Presentation of the Johann-Lukas-Schoenlein-Award -- I. Epidemiology -- HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 1999/2000 Survey) -- Hemophilia 2000 — the Annual Survey of the Austrian Hemophilia Centers -- II. Inhibitors in Hemophilia -- Changes in Epitope Specificity and in Distribution of FVIII Antibodies during Immune Tolerance Therapy (ITT) in Hemophilia A Patients with FVIII Antibodies — a Case Report -- Clinical Experience with the Modified Bonn-Malmö Protocol since 1996 -- Course of Inhibitors in mild Hemophilia A with and without Immune Tolerance Treatment -- III. Therapy and Monitoring of Bleeds in Acute- and Intensive Care Medicine -- Management of Bleeding in Surgery and Intensive Care -- IV.. Pediatric Hemostaseology -- Frequency and Profile of viral posttransfusional Infections in Patients from Hemophilia Center Timisoara -- Symptomatic Onset of severe Hemophilia A in Childhood is dependent on the Presence of Prothrombotic Risk Factors -- Differences between Neonates and Adults in Plasmin Inhibitory and Antifibrinolytic Action of Aprotinin -- Shorter PFA-100 Closure Times (CT) in Neonates than in Adults: Role of Red Cells, White Cells, Platelets, and von Willebrand Factor -- V. Free Lectures -- Efficacy and Safety of a High Purity Protein C Concentrate in the Management of Patients with severe Congenital Protein C Deficiency -- Respective Roles of Factors II, VII, IX, and X in the Procoagulant Activity of FEIBA -- Capillary Microscopic and Rheological Dimensions for the Diagnosis of von-Willebrand-Disease in Comparison with other Hemorrhagic Diatheses -- Evaluation of Denaturing High Performance Liquid Chromatography (DHPLC) in the Analysis of Hemophilia A -- Vla. Poster: Clinic and Casuistic -- Rheumatoid Arthritis in a Patient with Hemophilia Arthropathy — a Case Report -- Recurrent Fatal Intracranial Hemorrhage (ICH) in Two Non-Identical Twins suffering from Hemophilia B (Factor IX Activity < 1%) -- Progression of Thrombosis under Low Molecular Weight Heparin without Heparin-Induced Thrombocytopenia in a young Man: a Case Report -- Cardiac Tamponade in a Patient with acquired Factor VIII Inhibitor and Chronic Renal Failure -- Endoscopic Cholecystectomy in a 55-year-old Patient with Heparin-Induced Thrombocytopenia Type II and Replacement of Mitral and Aortic Valve and Tricuspidal Valve Anular Plasty -- Vlb. Poster: Hemophilia -- Successful Orthopedic Operations in Hemophilic Adults with Inhibitors against Factor VIII -- Evaluation of Clinical Efficacy of rFVIIa in Pediatrics -- Risk Factors for Thrombosis in Hemophilia — an Analysis -- Status of Pain in Patients with severe Haemophilic Arthropathies -- Results of a 5-year Clinical Study with a B-domain Deleted FVIII Concentrate (rFVIII-SQ) -- Outpatient Treatment with Radiosynoviorthesis in Hemophilic Arthropathy -- Requirements for Future Hemophilia Treatment from the Patients’ Point of View -- Vic. Poster: Hemorrhagic Diathesis -- Molecular Basis of von Willebrand Disease Type IIC Miami -- Hemorrhagic Diathesis through acquired Factor XIII Inhibitor -- Liver Transplantation in a Patient with severe von Willebrand Disease Type 3: Levels of von Willebrand Factor Following Transplantation -- Clincal Course and Laboratory Findings in a Patient with a New Mutation Causing Wiskott-Aldrich Syndrome -- Role of acquired and inherited Prothrombotic Risk Factors in Pediatric Cerebral Venous Thrombosis — Preliminary Results of a Multicenter Case-Control Study -- Analysis of the Fibrinogen Genes of 40 Patients with Suspicion of Dys-, Hypo- or Afibrinogenemia -- Vld. Poster: Thrombophilic Diathesis -- Hereditary Antithrombin Deficiency — Results of a Family Study -- Elevated Factor IX and Factor XI as Risk Factors for Venous Thrombosis and Stroke -- Thrombophilic Risk Parameters in Juvenile »Idiopathic« Stroke Patients -- Inquiry into the Significance of Constantly Raised FVIII Values as a Factor in Thrombophilia -- Do Statins Increase the Homocysteine Level? -- Alpha 2-Macroglobulin Level regulates the Anticoagulant Cofactor Activity of Protein S in Cord and Adult Plasma -- Combined Prothrombotic Defects and Contraceptives — Risk Factor for Deep Venous Thrombosis in Adolescence -- Role of 23 bp Insertion in Exon 3 of the Endothelial Cell Protein C Receptor Gene in Venous Thrombophilia.Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.Medicine.Anesthesiology.Critical care medicine.Blood transfusion.Hematology.Pediatrics.Medicine & Public Health.Hematology.Pediatrics.Anesthesiology.Blood Transfusion Medicine.Intensive / Critical Care Medicine.Springer eBookshttp://dx.doi.org/10.1007/978-3-642-59383-3URN:ISBN:9783642593833 |